How do we start antibiotics broadly

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Here's a comprehensive breakdown of how to start antibiotics broadly (empiric/broad-spectrum therapy):

Starting Antibiotics Broadly (Empiric Therapy)

What Is Empiric Therapy?

Empiric antibiotic therapy means starting a broad-spectrum drug that covers the most likely organisms before culture and sensitivity results return. It is based on a "best guess" derived from clinical context, not confirmed microbiology.

— Jawetz, Melnick & Adelberg's Medical Microbiology, 28e

Step 1 — Obtain Cultures First

Before starting empiric antibiotics, obtain appropriate diagnostic specimens:

Blood cultures (ideally ≥2 sets)
Urine culture (if UTI/urosepsis suspected)
Sputum/BAL (if pneumonia suspected)
Wound swabs, CSF, etc. as clinically indicated

Empiric therapy starts immediately after specimens are collected, not before.

Step 2 — Make the "Best Guess"

The likely causative organism is estimated using:

Factor	What to Consider
Site of infection	Pneumonia → respiratory pathogens; UTI → gram-negatives
Patient age	Neonates vs. adults have very different organisms
Community vs. hospital-acquired	HAP/VAP → resistant organisms; CAP → typical pathogens
Mechanical factors	Indwelling catheter, ventilator, IV lines
Host factors	Immunocompromised, transplant, cancer chemotherapy
Prior antibiotics	Major risk factor for MDR organisms
Local antibiogram	Critical — always check your institution's resistance patterns

Step 3 — Choose Broad Coverage

General principle: Cover the most dangerous likely pathogens, then de-escalate.

Common broad-spectrum regimens by context:

No MDR risk (low-risk ICU/hospital):

Piperacillin-tazobactam 4.5 g IV q6h, OR
Cefepime 2 g IV q8h, OR
Levofloxacin 750 mg IV q24h

MDR risk (prior antibiotics, prior hospitalization, resistant gram-negatives):

One anti-pseudomonal β-lactam (pip-tazo, cefepime, ceftazidime, imipenem, meropenem)
PLUS one aminoglycoside (amikacin, gentamicin, tobramycin) or fluoroquinolone

MRSA risk (known colonization, hemodialysis, ICU MRSA rate >10%):

Add vancomycin (trough 15–20 mg/dL) or linezolid 600 mg IV q12h

Severe soft tissue/necrotizing infection:

β-lactam/β-lactamase inhibitor + clindamycin + vancomycin (until MRSA excluded)

Surgical infections:

Carbapenem or fluoroquinolone + clindamycin covers mixed aerobic/anaerobic flora

— Harrison's Principles of Internal Medicine, 22e; Washington Manual of Medical Therapeutics

Step 4 — De-escalate as Soon as Possible

Once culture results return (typically 48–72 hours):

Narrow to targeted therapy based on sensitivities
Remove redundant agents (e.g., stop aminoglycoside if susceptibility is confirmed to β-lactam)
Switch IV → PO when appropriate

This "de-escalation" strategy reduces resistance pressure, toxicity, and cost.

Why Broad Empiric Therapy Can Be Harmful

Indiscriminate use carries real risks:

Widespread hypersensitivity/anaphylaxis
Disruption of normal flora → C. difficile, fungal overgrowth
Masking serious infection without curing it (e.g., abscess)
Direct toxicity (aminoglycosides → nephro/ototoxicity; cephalosporins → cytopenias)
Resistance selection — the most important long-term consequence

— Jawetz, Melnick & Adelberg's Medical Microbiology, 28e

Key Takeaway

Obtain cultures → Start broad → Know your local antibiogram → De-escalate early

The local antibiogram and the patient's prior antibiotic exposure are the two most important factors guiding empiric choice. A single agent is preferred when MDR risk is low; combination therapy is reserved for high-mortality-risk or high-resistance settings.

This is a shared conversation. Sign in to Orris to start your own chat.